Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study
Table 2
Ocular control of adalimumab (ADA) therapy, overall and stratified according to the concomitant use of DMARDs.
Observed
6 months
12 months
>12 months
Overall, N (%)
N. obs.
106
92
78
55
Ocular control
—
77 (83.7)
65 (83.3)
52 (94.6)
No ocular control
—
15 (16.3)
13 (16.7)
3 (5.5)
Stratified according to reason for ADA beginning:
Ocular (+/- systemic)
N. obs.
76
65
56
36
Ocular control
—
54 (83.1)
45 (80.4)
33 (91.7)
Systemic
N. observed
30
27
27
19
Ocular control
—
23 (85.2)
23 (90.9)
19 (100.0)
Stratified according to DMARD cotreatment in the first year:
Only ADA group, N (%)
N. obs.
29
25
20
18
Ocular control
22 (88.0)
17 (85.0)
17 (94.4)
ADA+DMARD group, N (%)
N. obs.
29
29
25
13
Ocular control
21 (72.4)
19 (76.0)
13 (100.0)
value
0.191
0.709
n.c.
value from the comparison of proportions of ocular control in the “only ADA” vs. “ADA+DMARD” groups; ADA: adalimumab; DMARDs: disease-modifying antirheumatic drugs; n.c.: not calculable.
